NCT05496465

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

A Single-Dose, Randomized, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: ARS Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Determine the effect of ARS-1 on a patient reported pruritus/hive score

Conditions

• Urticaria

Interventions

Type	Name	Description
DRUG	ARS-1	A single treatment of ARS-1 1mg, 2 mg or placebo

Timeline

• Start date: 2022-07-28
• Primary completion: 2024-02-29
• Completion: 2024-02-29
• First posted: 2022-08-11
• Last updated: 2026-04-07
• Results posted: 2026-04-07

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study